Treating cancer with selective CDK4/6 inhibitors

By B. O’Leary, R. Finn, N. Turner. Nature Reviews Clinical Oncology, 2016

1,014 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/9fc2e30b42668a597b1aa8c1c246575eca819607

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Kurt Engeland

Citations in the corpus

• Cell cycle regulation: p53-p21-RB signaling (2022, background): “In this regard, p53-p21-RB signaling can be rescued by CDK inhibitor drugs when function of p53 or p21 have been lost [54].”
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Gemcitabine 7 (3) 6 (3) 26 (20) 5 (4) 9 (8) 15 (18)”